3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Urinary Bladder Neoplasms
13
Glioblastoma
4
Brain Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Pancreatic Neoplasms
2
Neoplasms
2
Melanoma
2
Glioma
2
Astrocytoma
2
Urothelial Carcinoma of the Bladder
1
Prostatic Hyperplasia
1
Pathologic Complete Response
1
Paranasal Sinus Neoplasms
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroblastoma
1
Nasopharyngeal Carcinoma
1
Muscle-invasive Urothelial Cancer of the Bladder
1
Mouth Neoplasms
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Ganglioneuroblastoma
1
Estrogen Receptor Positive Breast Cancer
1
Ependymoma
1
Craniopharyngioma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Epirubicin
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Observation
2
Monatide (IMS 3015)
2
Metformin
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pathologic Complete Response
×
Transurethral Resection of Bladder
×
Clear all
NCT05684874
2023-10-30
SarQuantIRM
Centre Leon Berard
Phase NA
Unknown
25 enrolled